Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Glioma 4Glioblastoma 4Melanoma 3Leukemia, Myeloid, Acute 3Sarcoma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Astrocytoma 2Treatment 1Stomach Neoplasms 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Pathologic Complete Response 1Neurofibrosarcoma 1Neoplasms, Connective and Soft Tissue 1Neoplasms 1Neoplasm Metastasis 1Myosarcoma 1Microsatellite Instability 1Lung Neoplasms 1Liposarcoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Leiomyosarcoma 1

Interventions

Radiotherapy 6Doxorubicin 5Nivolumab 4pembrolizumab 3Sunitinib 3Ifosfamide 3Gemcitabine 3Docetaxel 3pazopanib 2Radiation Dose Hypofractionation 2Radiation 2Methotrexate 2Ipilimumab 2Cisplatin 2CTLA-4 Antigen 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1toripalimab 1temsirolimus 1spartalizumab 1sintilimab 1ribociclib 1regorafenib 1pegfilgrastim 1liposomal doxorubicin 1lentiviral minigene vaccine of COVID-19 coronavirus 1itacitinib 1fludarabine 1eribulin 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Histiocytoma, Malignant Fibrous × lentiviral minigene vaccine of COVID-19 coronavirus × Clear all
NCT01883518 2019-11-20

ADCVCTAST

N.N. Petrov National Medical Research Center of Oncology

Phase 1/2 Unknown
48 enrolled
Sarcoma

Chondrosarcoma, Fibrosarcoma, Leiomyosarcoma, Liposarcoma, Myosarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Neoplasms, Connective and Soft Tissue, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Histiocytoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡